compound used extensively in the rubber industry, is weakly carcinogenic in Sprague-Dawley rats after chronic exposures to concentrations of 1000 and 8000 ppm. Conversely, in B6C3F1 mice, tumors occur after chronic exposures to concentrations as low as 6.25 ppm. Previously, we have shown that tissue concentrations of the mutagenic BD metabolites, butadiene monoepoxide (BDO) and butadiene diepoxide (BDOj), are present in greater concentrations in mice than in rats following acute exposures to low levels (100 ppm or less). This disparity was particularly significant for the diepoxide. We hypothesized that if these epoxides are involved in the carcinogenic response of BD, then they will also be present in rat tissues at relatively high concentrations following exposures to 8000 ppm BD. In the present study, concentrations of the BD epoxides, BDO and BDO 2 , were determined in blood of female Sprague-Dawley rats following a single 6-h exposure and 10 repeated exposures to a target concentration of 8000 ppm BD. Concentrations of these epoxides were also determined in a number of other tissues, including the primary rat target organ-mammary gland-following 10 repeated exposures. Blood concentrations of BDO were 4030 pmol/ g ± 191 following a 6-h exposure and were 18% lower following the 10-day exposure. Blood concentrations of BDO 2 , following the 8000 ppm exposures, were very similar to those previously observed after exposures to 62.5 ppm BD (11 ± 1 and 17 ± 1 pmol/g following exposures of 6h and 6h/day for 10 days, respectively.) Concentrations of BDO ranged from 740 ± 110 (femur) to 8990 ± 1150 (fat) pmol/g tissue. Concentrations of BDO 2 were similar among eight tissues analyzed, ranging from 5 ± 1 (femur) to 17 ± 3 (heart) pmol/g tissue. Tissue concentrations of butadiene mono-' Current address:
epoxide were increased by 17-to 50-fold in tissues from rats exposed by inhalation to 8000 ppm BD as compared to tissues from rats exposed to 62.5 ppm BD. Based on earlier studies at our institute the internal dose of BD increases approximately 14-fold in the 8000 ppm-exposed rats compared to rats exposed to 62.5 ppm BD. Concentrations of butadiene diepoxide in rat tissues following an exposure to 8000 ppm BD were similar to those observed in rat tissues following exposures to 62.5 ppm BD. This study shows that pathways responsible for the accumulation of BDO 2 in rats are saturated following low-level BD exposures. This suggests that the primary determinant of BD tumorigenicity hi rats is not butadiene diepoxide. The high levels of BDO observed in rat mammary tissue suggest that this metabolite may be a more important determinant of BD carcinogenesis in the rat. c 1998 Society of Toxicology.
Key Words: 1,3-butadiene; metabolism; butadiene monoepoxide; butadiene diepoxide. 1,3-Butadiene (BD), an industrial chemical used in the production of polybutadiene and styrene-butadiene rubber, is among the top 50 chemicals produced in the United States (Chem. Eng. News, 1995) . The United States Environmental Protection Agency (EPA) has listed BD as one of the hazardous air pollutants in the 1990 Clean Air Act Amendment (EPA, 1991) . It has been estimated that as many as 65,000 workers are potentially exposed to BD in chemical industries in the United States (Choudary, 1994) . BD is also present in cigarette smoke and automobile exhaust, resulting in low-level exposures of this compound to most of the population (Miller, 1978) .
BD and its metabolites are genotoxic in a number of assays, and BD is a multiple organ carcinogen in both rats and mice (reviewed by Himmelstein et ai, 1997) . Profound species differences exist between rats and mice in the potency and organ-site specificity of BD carcinogenicity and in the metabolism of BD. Treatment-related increases in Leydig cell tumors, and mammary gland and thyroid neoplasms were observed in Sprague-Dawley rats exposed to 1000 and 8000 ppm BD for 6h/day, 5 days/week for 2 years (Owen et al, 1987) . In B6C3F1 mice, tumors were induced following chronic exposures ranging from 6.25 to 625 ppm. Tumor types included alveolar-bronchiolar carcinomas, hemangiosarcomas of the heart, lymphomas, and neoplasms of the forestomach, Harderian gland, preputial gland, liver, mammary gland, and ovary (Melnick et al., 1990) . The mechanism of these species differences in BD-induced carcinogenicity has been suggested to be due to species-related differences in the production and disposition of reactive BD epoxide metabolites (Bechtold et ai, 1995; Thornton-Manning et ai, 1995a Himmelstein et ai, 1994 Himmelstein et ai, , 1995 Himmelstein et ai, , 1996 .
The primary initial step of BD metabolism is the cytochrome P450-mediated production of butadiene monoepoxide (BDO) (Bolt et al, 1983; Schmidt and Loeser, 1985; Duescher and Elfarra, 1994) . BDO is further oxidized by cytochrome P450 enzyme(s) to form butadiene diepoxide (BDO 2 ) (Malvoisin and Roberfroid, 1982) . Both epoxides are also substrates for glutathione S-transferases and epoxide hydrolases (Csan&dy et al., 1992; Boogaard et al., 1996) . Genotoxicity studies have indicated that while both epoxides are mutagenic in a number of in vitro tests, the diepoxide is a more potent mutagen (Cochrane and Skopek, 1994; Voogd et al., 1981) .
Our laboratory (Bechtold et al., 1995; Thornton-Manning et al., 1995a ,b, 1996 and others (Himmelstein et al., 1994 (Himmelstein et al., , 1995 (Himmelstein et al., , 1996 have used GC/MS methods to identify and quantify concentrations of BDO and BDO 2 in blood and other tissues of rats and mice following short-term inhalation exposures to BD. Consistently, concentrations of BDO were found to be greater in mouse tissues than in rat tissues following exposures to concentrations of BD ranging from 62.5 to 1250 ppm. BDO 2 was present in high concentrations in the blood of mice following inhalation exposures ranging from 62.5 to 1250 ppm BD (Himmelstein et ai, 1994; Bechtold et ai, 1995; Thornton-Manning et ai, 1995a) . This metabolite was present in the blood of rats following low-level exposures, but at concentrations that are about 40-fold lower than those found in mice (Thornton-Manning et ai, 1995a) . Himmelstein and coworkers (1995) conducted exposures of rats to 8000 ppm BD, but were unable to quantify BDO 2 in blood or other tissues due to analytical limitations.
The potent genotoxicity of BDO 2 , as well as its presence in high concentrations in mouse target tissues following exposures to BD, has led investigators to postulate that this compound may be the primary determinant of BD carcinogenicity (Bond et ai, 1995) . We hypothesized that if BDO 2 is important in the ultimate carcinogenic response of BD in rats that it would be present in large concentrations (similar to those observed in mice following exposures to low levels of BD) in rat target organs following exposures of rats to 8000 ppm BD. The purpose of this study was to quantify concentrations of BDO and BDO 2 in rat tissues following a 10-day exposure to 8000 ppm BD and to compare these data to those obtained from previous studies in which rats were exposed to 62.5 ppm BD for 10 days. Furthermore, concentrations of the epoxides were compared in blood following a single 6-h exposure and 10 repeated exposures.
MATERIALS AND METHODS
Chemicals. BD, BDO (1,2-epoxy-3-butene), and BDO 2 (±-l,2,3,4-diepoxybutane) were obtained from Aldrich Chemical Company (Milwaukee, Wl) at the highest possible purities (&98%). Deuterated BDO (BDO-d 6 ) and BDO 2 (BDO 2 -d 6 ) were synthesized as previously described (Maples et al., 1992) . Methylene chloride (HPLC grade) was purchased from Sigma-Aldrich Company (St. Louis, MO). Stock solutions of BDO, BDO 2 , BDO-d 6 , and BDO 2 -d 6 were diluted in milli-Q water and maintained in liquid nitrogen. The purity of BD was checked by GC/MS and the purities of stock solutions of the epoxides were checked by IR spectroscopy and determined to be >99%.
Animals and animal husbandry. Female Sprague-Dawley [Hsd: Sprague
Dawley SD] rats were purchased from Harlan Sprague-Dawley Inc. (Indianapolis, IN), placed in polycarbonate cages (two rats per cage), and quarantined for 2 weeks prior to exposures. The animals were 11 to 14 weeks old with body weights of 190 to 228 g for rats. The animals were conditioned twice to the nose-only exposure tubes, once for lh and again for 2h, within 4h prior to initiation of the exposures. Food (Lab-Blox, Allied Mills, Chicago, IL) and water were provided ad libitum, except during the exposures. This study was approved by the Inhalation Toxicology Research Institute Animal Use and Care Committee prior to initiation.
Inhalation exposures. Nose-only inhalation exposures were carried out as previously described on a multiport, nose-only system (Bechtold et al., 1995; Thornton-Manning et ah, 1995a) . Temperature was maintained at 18 to 22°C inside the enclosure used to house the exposure system to ensure that the animals were kept at a sufficiently cool temperature while in the exposure tubes. Oxygen concentrations were maintained at ~20% during the exposure. Temperature, oxygen concentration, and time of day were logged every 5 min by Labtech Notebook (Laboratory Technologies Corp., Wilmington, MA) data acquisition software. BD atmospheres were generated directly from cylinders of BD diluted with filtered house air. The BD cylinder (0-100 ccm) and dilution air (Dynablend) were run through mass flow controllers (Matheson, East Rutherford, NJ).
BD concentrations in the exposure chambers were quantified by a GC (Perkin Elmer, Model 8700) equipped with a flame ionization detector. The carrier gas was helium and the flow rate was 30 ml/min. A Tenax SS column (6 ft X 0.085 rn.), was maintained isothermally at 100°C. Standard curves were generated during each exposure and used to quantify BD. Samples were taken automatically from the exposure chamber every 5 nun. Peak areas from the GC were quantified using a Spectra Physics 4270 integrator. Real-time changes in BD concentrations in the exposure system were monitored by IR spectroscopy (Miran) at a wavelength of 3.4 /JJTI. The target concentration in these studies was 8000 ppm.
Control animals were exposed to filtered house air on an exposure plenum identical to that used for the BD exposures. The control plenum was maintained outside the enclosure which housed the BD exposure plenum and the animals were placed on the BD exposure plenum and the control plenum alternately, such that controls were exposed to house air during the same time that the treated animals were exposed to BD. The animals were weighed several times during the 10-day exposure.
Collection of tissues from rats and mice. Animals were anesthetized at 5h 55 min following initiation of the exposure to BD on Day 10 (or on Day 1 for animals used in acute blood collection). Special exposure tubes equipped with airtight sleeves which covered a small window over the thorax of the rodent allowed for collection of blood via cardiac puncture while the animals were still breathing the exposure atmosphere. After the animals were anesthetized, the sleeves were drawn back and blood was collected from the animals via cardiac puncture. One milliliter of blood from each of three rats was removed and pooled into a round-bottom flask maintained in liquid nitrogen. The animal was then taken from the exposure plenum and other tissues including lung, fat, femurs, hearts, uteri, and ovaries were removed and placed in liquid nitrogen within 5 to 7 min. Mammary tissue was removed by reflecting the skin from the abdomen and bluntly dissecting the inguinal mammary tissue bilaterally. It was immediately placed in liquid nitrogen. Blood and tissues from three rats were pooled at the time of collection. Internal standards (deuterated BDO and BDOJ were added to the blood at the time of collection. Immediately prior to cryogenic distillation (described below), the tissues were removed from liquid nitrogen, pulverized, and placed into preweighed flasks containing internal standards. The flasks were reweighed to determine tissue weights.
Preparation of samples for analysis. The tissue samples were prepared for analysis by vacuum line-cryogenic distillation (Thornton-Manning et al, 1995) . The samples, contained in round-bottomed flasks, were distilled into two cryogenic traps on a 10-port manifold which was maintained at <10~2 Torr. The first trap, held in a xylene slush at 45°C, trapped water and other volatiles of similar vapor pressure. The metabolites eluted into the second trap, a septaport U-trap (a U-tube modified with a sampling port and Teflon closures) held in liquid nitrogen. Following the distillation, the septaport U-traps were closed and removed from the vacuum line. Methylcne chloride (100 jiX) was added to the U-trap through the septum and the contents of the trap were shaken vigorously for several seconds. The contents of the trap were then removed and analyzed by GC/GC/MS as described below.
Analysis of metabolites. The BD metabolites were analyzed by GC/ GC/MS as previously described (Bechtold et al., 1995; Thornton-Manning et al., 1995a) . Methylene chloride (20 /xl) containing BD metabolites was analyzed using a GC/GC/MS system which was composed of a Hewlett Packard 5890 GC, a 5970 Mass Selective Detector, a Hewlett Packard-UX Datastation (Hewlett Packard Corp., North Hollywood, CA), a Nelson Analytical Datastation (Nelson, Cupertino, CA), and a custom-built interface for column switching and cryogenic focusing. The GC utilized a Restek RTx-1 capillary column (Restek, Bellefonte, PA), 30 m X 0.53 mm i.d., with a 5.0-/xm film thickness (100* crossbanded polysiloxane) and a DB-Wax capillary column, 40 m X 0.18 mm i.d., with a 0.30-/xm film thickness (100% polyethylene glycol) (J&W, Folsom, CA). The MS was operated in the selected ion-monitonng mode. For BDO and BDO 2 , ions 39,69 and 29,55 were monitored, respectively. For the internal standards, BDO-d 6 and for BDO 2 -d 6 , ions 46,74 and 30,58 were monitored. Contribution of 2-butanone, an impurity that coelutes with BDO, was determined by monitoring ion 57 and subtracting the amount of ion 39 resulting from 2-butanone from the total peak area ( Thomton-Manning et aL, 1995a) . Quantitations for BDO were based on the ratio of ions mlz 39/46, while those for BDO 2 were based on the ratio for ions mlz 55/58. Standard curves generated by adding known amounts of metabolite standards to distilled milliQ water and internal standard were used to quantify tissue concentrations of the epoxides. These samples were extracted with methylene chloride and analyzed as described above. The standard curves had correlation coefficients > 0.93.
The instrument detection limit for BDO 2 using the methods described above was 1.2 pmol, as previously described (Thornton-Manning el al., 1995a) . Instrument detection limits for BDO were not determined because a low background of BDO-like substances was present in all control tissues. These values were subtracted from exposed values. Data analysis. Epoxide levels in both control and exposed tissues were quantified from standard curves. The standard curve for BDO 2 was forced dirough the origin. To avoid statistical analysis of the negative values that occasionally occurred in our chemical analyses, a value of 30 was added to data before it was log transformed. The data were log transformed to make them approximately normally distributed because as in our previous studies the estimated variances were approximately proportional to the means. Also, as in our previous studies of butadiene, one-way analysis of variance was used to analyze the data. Because all comparisons involved only two groups, the one-way analysis of variance is equivalent to a r test with a common variance. Further testing for homogeneity of variance was not justified because of the small size of the experimental groups. Values were considered significantly different when p £ 0.05.
RESULTS
Exposure. The mean of the actual concentrations for the 10 exposures was 7119 ± 2.93 ppm (mean ± SE; n = 88). Exposure concentrations remained stable throughout each 6-h exposure. There was no marked decrease in mean weights of the animals in the control or exposed group during the course of the exposure.
Concentrations of BD epoxides in rat blood following a single and 10 repeated exposures to 8000 ppm BD. Concentrations of BDO and BDO 2 in blood following single or repeated exposures are shown in Table 1 . BDO concentrations did not differ significantly (p ^ 0.05) in the blood of animals exposed for 10 days as compared with blood from animals exposed for only 6h. However, concentrations of BDO 2 were approximately 50% greater in blood from animals exposed repeatedly to BD as compared with blood from animals exposed for 6h.
Concentrations ofBD epoxides in several rat tissues following 10 repeated exposures to 8000 ppm BD. Concentrations of BDO and BDO 2 in rat tissues following exposures to 8000 ppm are shown in Table 2 . BDO concentrations were lowest in the femur (740 ±110 pmol/g tissue; mean ± SE) and highest in fat (8990 ± 1150 pmol/g tissue). Concentrations of BDO 2 were greatest in blood and hearts and lowest in femurs. ning et al., in press) . Asterisks indicate values from tissues of rats exposed to 8000 BD that are statistically different from values for tissues from rats exposed to 62.5 ppm BD, p •<. 0.05.
Comparisons of rat blood and tissue epoxide concentrations following repeated exposures to 8000 and 62.5 ppm BD.
Comparisons of blood and tissue concentrations of the epoxides following repeated exposures at 8000 ppm were compared with tissue concentrations of the epoxides from previous studies in which repeated exposures to 62.5 ppm BD were conducted (Thornton-Manning et al., in press ). Concentrations of BDO were significantly (p ^ 0.05) greater in the blood and tissues from the animals exposed to 8000 ppm as compared with those exposed to 62.5 ppm (Fig. 1) . BDO was 50-fold higher in the blood of rats repeatedly exposed to the higher concentration compared to the lower concentration. BDO was present in fat from the 62.5 ppm-exposed animals at a concentration of 423 ± 35 pmol/g and was present in fat from the 8000 ppm-exposed animals at a concentration that was 21-fold greater. BDO was not detected in lungs of rats exposed for 10 days to 62.5 ppm BD, but was present at a concentration of 1240 ± 210 pmol/g in lungs of rats exposed to 8000 ppm BD for 10 days. The concentration of BDO in the mammary gland of rats exposed repeatedly to 8000 ppm BD was approximately 16-fold greater than in rats similarly exposed to 62.5 ppm BD, while the concentrations in the femur were approximately 40-fold greater.
Concentrations of BDO 2 were similar in blood and tissues of rats repeatedly exposed to 8000 and 62.5 ppm BD (Fig. 2) . The concentrations of BDO 2 in the blood were the same following either exposure. In femurs and mammary tissue, the concentrations were lower following exposures to 8000 ppm as compared with those tissues taken from animals exposed to 62.5 ppm. However, this difference, while statistically significant, was only approximately twofold. In the lungs, concentrations of the diepoxide were greater by 126% in animals exposed to 8000 ppm as compared with animals exposed to 62.5 ppm BD.
DISCUSSION
Several lines of evidence support the contention that BDO 2 is the primary determinant of BD carcinogenicity. First, genotoxicity data indicate that BDO 2 is a more potent mutagen than the other epoxide metabolites of BD: BDO and 3-butene-l,2-diol (reviewed by Himmelstein et al, 1997) . Second, relative to those of rats, mouse target organs have higher concentrations of BDO 2 following inhalation exposures to BD (Thornton-Manning et al., 1995a) . Third, in vivo genotoxicity tests show that micronuclei occur in mice exposed to BD, consistent with the formation of deletions, which are genotoxic events associated with BDO 2 (Adler et al, 1994; Autio et al, 1994) .
A major finding of the present study is that following inhalation to a carcinogenic dose of BD, rat tissue concentrations of BDO 2 are essentially identical to those observed following low-level inhalation exposures. This suggests that BDO 2 is not the primary determinant of BD carcinogenicity in rats. Conversely, concentrations of BDO increased by as much as 50fold following exposures to the higher concentrations of BD. The 8000 ppm exposure concentration is 128-fold higher than the 62.5 ppm concentration, but, based on earlier toxicokinetic studies from our institute, the BD retained by animals exposed by inhalation to the two concentrations would be only 14-fold higher after the 8000 ppm (based on single, 6-h exposures to 14 C-BD; Bond et al, 1986) . Thus the BDO in the tissues increased according to the increase in the internal dose of BD, with greater than expected increases in blood and femur concentrations.
Studies have shown both similarities and differences in BD metabolism between rats and mice. Diethyldithiocarbamate has been shown to inhibit BD uptake in both rats (Bolt etal, 1994) 20-i | Exposure Concentration 62.5 pom 8000 ppm
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Lung Mammary   FIG. 2. Comparisons of blood and tissue concentrations of a BDO 2 (mean ± SE) following repeated (10X) high-and low-level exposures. Data for low level (62.5 ppm) exposures of rats were previously reported (Thomton-Manning et al, in press) . Asterisks indicate values from tissues of rats exposed to 8000 BD that are statistically different from values for tissues from rats exposed to 62.5 ppm BD, p £ 0.05. and mice (Kreiling et al., 1986) , suggesting that CYP2E1 plays a major role in BD metabolism. This is consistent with in vitro studies using human liver microsomes showing that CYP2E1 is involved in BD metabolism to BDO (Csanidy et al, 1992) . The differences in BD metabolism involve mainly detoxication pathways. Csana'dy and co-workers (1992) showed that V ma JK m for the hydrolysis of BDO was greater for rat liver microsomes than mouse liver microsomes. Conversely, capacity for GSH conjugation was greater in mice than in rats. GSH conjugation rates for BDO 2 using liver cytosolic fractions are similar between rats and mice (Boorgard et al., 1996) . The present study shows another important difference in BD metabolism between rats and mice. Pathways responsible for the accumulation of BDO 2 are saturated following low-level exposures in rats. In B6C3F1 mice exposed to 62.5, 625, and 1250 ppm BD, dose-related increases in both BDO and BDO 2 were observed (Himmelstein et al, 1994) .
The exact mechanism by which tissue concentrations of BDO 2 do not increase with dose in rats is not clear. Because concentrations of BDO continue to increase in a dose-related fashion, it can be concluded that the concentration of BDO 2 in tissues is an indication of balance between production of BDO 2 from BDO and elimination of BDO 2 . This involves elimination of BDO by GSH conjugation, hydrolysis, or conversion to BDO 2 and elimination of BDO 2 by GSH conjugation and hydrolysis. Tissue distribution and covalent binding of metabolites to cellular macromolecules also is involved in this balance. It is possible that the apparent saturation of pathways involves competition of parent compound and BDO for the same activating enzyme. This is supported by the fact that both BDO and BD have been shown to be substrates for CYP2E1 (Deuscher and Elfarra, 1994; CsanSdy et al., 1992; Seaton et al., 1996) . Examination of data reported by Himmelstein et al. (1994) indicates that BDO 2 does not increase linearly in mice following exposures to concentrations of BD between 62.5 and 1250 ppm. This suggests that metabolic pathways responsible for its accumulation also become saturated in mice following exposures to high levels of BD, albeit apparently more slowly than that which occurs in rats.
Repeated exposures at concentrations of 8000 ppm BD were apparently able to alter the activity of xenobiotic-metabolizing enzymes. Blood concentrations of BDO 2 were significantly greater in animals exposed for 10 days as compared with those exposed for only 6h. This could be due to either induction of activating enzymes or inhibition of detoxication enzymes. CYP2E1 is thought to be the primary P450 responsible for metabolism of both BD and BDO (reviewed by Himmelstein, 1996) . Because BDO concentrations did not increase following repeated exposures to BD, it is not likely that this isoform is induced. However, other isoforms which accept BDO as a substrate (but not BD) may have been induced. Inhibition of isoforms of GSTs or epoxide hydrolase which metabolize BDO 2 but not BDO may have occurred. Studies with human lymphocytes from individuals with GSTMJ null genotype or GSTT1 null genotype suggest that different GST isoforms are responsible for metabolism of BDO and BDO 2 Weincke et al., 1995; Norppa et al, 1995) .
Previous work in our laboratory examined changes in BD metabolite dosimetry in rats and mice following single and repeated exposures to 62.5 ppm BD (Thornton-Manning et al, submitted). Only minor changes were observed in mice-small increases of BDO in mammary and fat tissue and decreases of BDO 2 in lung, mammary, and fat tissue. BDO concentrations in lungs of rats exposed to 8000 ppm BD for 6h were previously reported to be 1300 ± 200 (mean ± SE) pmol/g tissue (Himmelstein et al., 1995) . This compares well with the value of 1240 ±210 found in the present study for lung BDO concentrations. Blood BDO concentrations in the present study (4030 ±190 pmol/g) were greater than those reported by Himmelstein and coworkers (1400 ± 70 pmol/g).
Following repeated exposures of rats to 8000 ppm BD, the greatest concentration of BDO was observed in fat tissue. The fat BDO concentration is consistent with that expected based on previously published partition coefficients (Medinsky et al., 1994) . Previously, we observed that following acute exposures to low levels (62.5 ppm) of BD, fat concentrations of BDO were greater than would be expected (Thornton-Manning et al, 1995a) . This suggests that tissue distribution of the metabolites may markedly differ depending on exposure concentration. This may be due to induction or inhibition of xenobioticmetabolizing enzymes at the higher exposure level.
Mammary tissue is the primary target of carcinogenesis in the rat (Owen et al, 1987) . The low concentrations of BDO 2 detected in this tissue suggest that this metabolite is probably not the major determinant of mammary carcinogenesis. However, BDO is present in relatively large concentrations in this tissue, and hence may play a role in mammary carcinogenesis. Following repeated exposures to low levels of BD (62.5 ppm), mammary tissue levels of BDO were 291.4 ± 25.3 pmol/g (mean ± SE), approximately 4.6-fold greater than those of blood.
Available data suggest that BDO 2 is an important determination of BD carcinogenicity in mice. However, the mechanism of BD carcinogenesis in rats is not well understood. This study suggests that BDO 2 may not play a role in BD carcinogenesis in the rat However, it is possible that BDO is important in the ultimate carcinogenic effect in the rat. This might explain the species differences in tissue-specificity with regard to carcinogenesis in the rat and mouse. Concentrations of BDO in mouse lungs following repeated exposures to 62.5 ppm BD were 153 ± 78 pmol/g ( Thornton-Manning et al, 1997) . In rats, lung BDO concentrations were 1240 ± 210 pmol/g following repeated exposures to 8000 ppm BD. This suggests that BDO is not responsible for lung tumorigenesis, since mice, but not rats, develop lung tumors from chronic BD exposure. However, mammary BDO concentrations were 1200 ±130 pmol/g in mice following repeated low-level exposures and 4850 ± 450 pmol/g in rats following high-level exposures. Because both rats and mice developed mammary tumors after chronic exposures, it is possible that mammary tumors are due to BDO.
This study shows that the accumulation of the highly mutagenic diepoxide in target tissues is probably not an important determinant of BD-induced tumorigenesis in rats. Furthermore, saturation of metabolic pathways responsible for the accumulation of BDO 2 appears to occur in rats following low exposures to BD. This may explain why rats are not as susceptible to BD-induced carcinogenesis as mice and may be an important variable to consider with regard to BD metabolism in humans.
